Latvia MGI Tech SIA Advances DNA Methylation Research with Significant European Funding

10 нояб. 2023 г.

News

Latvia MGI Tech SIA Advances DNA Methylation Research with Significant European Funding
Latvia MGI Tech SIA Advances DNA Methylation Research with Significant European Funding
Latvia MGI Tech SIA Advances DNA Methylation Research with Significant European Funding
Latvia MGI Tech SIA Advances DNA Methylation Research with Significant European Funding

In a landmark move for scientific innovation, Latvia MGI Tech SIA has made significant strides in DNA methylation research, backed by robust European funding and collaborative efforts.

On January 30, 2020, Latvia MGI Tech SIA, a pioneering company in biotechnology, inked a critical agreement (No. VP-L-2022\79) with the Investment and Development Agency of Latvia. This agreement, under the aegis of the Operational Program “Growth and Employment,” specifically targets the enhancement of private sector investment in research and development (R&D). It aligns with the 1.2.1. specific aid objective to “Increase private sector investment in R&D” and the 1.2.1.2. activity “Support for the improvement of the technology transfer system.”

The core objective of this project is to conduct industrial research focusing on identifying reagents apt for DNA methylation detection and to optimize the conditions for these reactions. DNA methylation, a crucial process in genetic regulation, has far-reaching implications in medical and biological research.

In a subsequent development, on March 20, 2023, Latvia MGI Tech SIA formalized a service agreement with the Latvian Institute of Organic Synthesis. This collaboration was aimed at conducting a feasibility study, crucial for advancing their research. The research work, which concluded in October 2023, adhered strictly to the set technical specifications and was completed within the anticipated six-month timeframe.

The financial framework of this project is also noteworthy. The total investment for this ambitious project stands at EUR 29,825, excluding VAT. Notably, a substantial portion of this – EUR 25,000 – is co-financed by the European Regional Development Fund, underscoring the project's significance and the European Union's commitment to fostering scientific innovation.

Conclusion: The successful completion of this research project marks a significant milestone for Latvia MGI Tech SIA and the broader scientific community. The outcomes of this project are expected to lay the groundwork for further development and validation of new methods in DNA methylation research, potentially opening new avenues in genetic studies and medical research.

Project no. VP-PI-2022/86 and identification number 1.2.1.2/16/I/001 of the project "Technology Transfer Program" of the European Regional Development Fund.


About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

DNA Methylation

MGI-Tech

European Regional Development Fund

Share this article :

Elevating Precision Health: MGI Tech and Eurofins Genomics Unite with DNBSEQ-T20×2 Sequencer
Elevating Precision Health: MGI Tech and Eurofins Genomics Unite with DNBSEQ-T20×2 Sequencer

4 мар. 2024 г.

Elevating Precision Health: MGI Tech and Eurofins Genomics Unite with DNBSEQ-T20×2 Sequencer

MGI Tech has joined forces with Eurofins Genomics Europe Genotyping A/S, marking a pivotal moment in the advancement of large-scale genomic projects. This partnership heralds the first corporate order of the DNBSEQ-T20×2 ("T20") ultra-high throughput sequencer in Europe.

MGI's DNBSEQ-T20*x2 Wins 2023 Globee® Awards for Medical Equipment
MGI's DNBSEQ-T20*x2 Wins 2023 Globee® Awards for Medical Equipment

10 июл. 2023 г.

MGI's DNBSEQ-T20*x2 Wins 2023 Globee® Awards for Medical Equipment

Explore MGI's latest achievement as its DNBSEQ-T20×2 gene sequencing platform wins the prestigious Globee® for Medical Equipment in the 15th Annual 2023 Golden Bridge Business and Innovation Awards®. This post highlights MGI's commitment to innovation in the life science industry, their groundbreaking T20 gene sequencer, and how their technology is reshaping healthcare outcomes and the genetic industry.

Unveiling MGI's Groundbreaking Innovations at the ESHG Conference in Glasgow
Unveiling MGI's Groundbreaking Innovations at the ESHG Conference in Glasgow

14 июн. 2023 г.

Unveiling MGI's Groundbreaking Innovations at the ESHG Conference in Glasgow

Discover the groundbreaking partnerships and innovations unveiled by MGI Tech Co., Ltd. at the ESHG Conference in Glasgow. Learn about MGI's strategic collaborations in the European life sciences market, their advancements in sequencing and automation technologies, and their commitment to revolutionizing genomics research. This post also highlights MGI's strategic partnership with Alithea Genomics, aiming to innovate in RNA sequencing.

Join our newsletter to stay up to date on features and releases.

I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Join our newsletter to stay up to date on features and releases.

I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Join our newsletter to stay up to date on features and releases.

I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.